Researchers have said that an HIV (human immunodeficiency virus) drug could stop many coronavirus diseases, including the SARS-CoV-2 variants when given to infected cells at the right concentration.
The researchers have previously shown that a booster drug called — “cobicistat”, which is normally used to reinforce the effect of anti-HIV drugs, could have antiviral properties against a SARS-CoV-2 variant circulating in Europe in early 2020.
In the study, published in the journal Antiviral Research, the researchers investigated whether the anti-SARS-CoV-2 properties of cobicistat were maintained against the key variants of concern (VOCs) of SARS-CoV-2 and other coronaviruses, including Middle East respiratory syndrome coronavirus (MERS-CoV).
With a death rate of over 30 per cent, MERS-CoV circulates throughout the Middle East, Africa, and South Asia without a vaccine or specific treatment.
The researchers also compared cobicistat’s effects to those of ritonavir, a structurally similar molecule that is also one of the components of Paxlovid, the current gold standard for antiviral treatment of SARS-CoV-2.
